Condition

Stage III Squamous Cell Carcinoma of the Hypopharynx

ClinicalTrials.gov condition label

Clinical trials5

Recruiting0

Common interventions9

Lead sponsors shown2

Clinical trials

5 shown

Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck CancerNCT01528137 · 2012-05-01

Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerNCT00101348 · 2005-01-01

Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid TumorsNCT00089362 · 2004-07-01

Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerNCT00068497 · 2003-08-01

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and NeckNCT00063895 · 2003-04-01

Common interventions

laboratory biomarker analysisOTHER4 erlotinib hydrochlorideDRUG2 pharmacological studyOTHER2 alvespimycin hydrochlorideDRUG1 bevacizumabBIOLOGICAL1 cetuximabBIOLOGICAL1 gefitinibDRUG1 pharmacogenomic studiesOTHER1 talactoferrinBIOLOGICAL1

Leading sponsors

National Cancer Institute (NCI)4 Stanford University1

Trial status mix

COMPLETED4

TERMINATED1

Phase mix

PHASE14

PHASE22

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.